Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07476001 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC

Name: Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC — clinical trial record (NCT07476001)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorH. Lee Moffitt Cancer Center and Research Institute

Started2026-03-03

View on ClinicalTrials.gov ↗

Amendment history

2026-05-14

Study Status v1

Start dateestimated 2026-03→confirmed 2026-03-03

2026-03-12

Original filing

H. Lee Moffitt Cancer Center and Research Institute

209 trials monitored

See 17 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.

Trial Details

NCT Number	NCT07476001
Lead Sponsor	H. Lee Moffitt Cancer Center and Research Institute
Conditions	Metastatic Castration-resistant Prostate Cancer
Enrollment	12 participants
Start Date	2026-03-03
Primary Completion	2027-09 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-15